image

Investors

Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

RSS (Really Simple Syndication) feeds provide an easy way to keep up with news and information about our company. Most web browsers have built in RSS readers, or you can use our feeds in an RSS reader or aggregator.

Latest Press Releases

Latest SEC Filings

Recent Events